论文部分内容阅读
目的研究胸腺肽α1对成人急性非淋巴细胞性白血病(adultANLL)诱导化疗免疫功能的影响。方法采用流式细胞仪(FCM)检测诱导化疗前后患者的外周血T淋巴细胞亚群及NK细胞,采用ELISA方法检测IFN-γ的水平,随机分为治疗组(应用胸腺肽α1+诱导化疗组)和对照组(诱导化疗组),每组各27例,进行对照比较。结果诱导化疗前治疗组外周血中CD3+、CD4+、CD8+、CD4+/CD8+、CD3-CD16CD45与对照组接近(P>0.05),但CD3+、CD8+、NK数值诱导化疗2疗程后治疗组高于对照组,差异有显著性(P<0.05),而诱导化疗1疗程及诱导化疗2疗程后CD4+/CD8+、CD4+及短期CR组差异无显著性(P>0.05)。所有患者与正常组差异均有显著性(P<0.01);ANLL患者IFN-γ水平与正常人差异有显著性,均较正常组明显下降(P<0.01),但治疗组与对照组差异无显著性(P>0.05)。结论应用胸腺肽α1可以提高成人急性非淋巴细胞性白血病诱导化疗免疫功能,利于患者康复及进一步治疗,延长患者生存期。
Objective To investigate the effect of thymosin α1 on the immune function of adult acute non-lymphocytic leukemia (adultANLL) induced by chemotherapy. Methods Flow cytometry (FCM) was used to detect T lymphocyte subsets and NK cells in peripheral blood of patients before and after induction of chemotherapy. ELISA was used to detect the level of IFN-γ, and then randomly divided into treatment group (thymosin α1 + induction chemotherapy group) and Control group (induction chemotherapy group), each group of 27 cases, for comparison. Results The levels of CD3 +, CD4 +, CD8 +, CD4 + / CD8 + and CD3-CD16CD45 in the peripheral blood of the pretreatment group were similar to those of the control group (P> 0.05), but the values of CD3 +, CD8 + (P <0.05). There was no significant difference in CD4 + / CD8 +, CD4 + and short-term CR after 1 course of induction chemotherapy and 2 courses of induction chemotherapy (P> 0.05). All the patients had significant difference with the normal group (P <0.01). The level of IFN-γ in ANLL patients was significantly lower than that in the normal group (P <0.01), but there was no difference between the treatment group and the control group Significance (P> 0.05). Conclusion The application of thymosin α1 can improve the immune function of induction chemotherapy in acute non-lymphocytic leukemia patients, which is beneficial to the patients’ rehabilitation and further treatment and prolong the survival of patients.